Stroke, Vol 20, 1724-1729, Copyright © 1989 by American Heart Association
S Tanaka, M Tanaka and A Akashi
We studied the effect of chronic antihypertensive treatment with
budralazine on the lower blood pressure limit of cerebral blood flow
autoregulation using spontaneously hypertensive rats. Cerebral blood flow
in the parietal cortex and caudate nucleus was measured to determine the
lower limit using the hydrogen clearance method. The lower limit in both
cerebral regions was significantly higher in 10 untreated spontaneously
hypertensive rats than in 10 Wistar-Kyoto rats. The upward-shifted lower
limit was restored to close to normal in the caudate nucleus and was
partially restored in the parietal cortex of nine rats by 9 weeks of
treatment with the high dose (50-68 mg/kg/day) of budralazine, which kept
blood pressure constant at approximately normotension during the treatment
period; the lower limit was slightly restored in both cerebral regions of
seven rats by 4 weeks of treatment with the high dose. However, 9 weeks of
treatment with the low dose (19- 27 mg/kg/day) of budralazine, which
produced moderate continuous hypotension in nine rats, did not apparently
influence the lower limit. Our results suggest that long-term
antihypertensive therapy with budralazine reduces the upward-shifted lower
blood pressure limit of cerebral blood flow autoregulation toward normal
and that the restoration induced by budralazine depends on the degree of
blood pressure reduction as well as on the duration of the therapeutic
period.
ARTICLES
Influence of antihypertensive treatment with budralazine on autoregulation of cerebral blood flow in spontaneously hypertensive rats
Research Institute, Daiichi Pharmaceutical Co., Ltd., Tokyo, Japan.
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1989 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |